NGeneBio establishes 'NGeneBioAI' a US corporation...Full-scale entry into the US
Monday, July 24, 2023
NGeneBioAI is a corporation in which NGeneBio has invested 100% of its capital , and will play a role as a bridgehead for NGeneBio's 'NGene Precision Diagnosis Platform ' to fully enter the US in the US cancer diagnosis market worth about $ 4.1 billion.
NgenBio plans to promote cancer data analysis service development of AI- based precision diagnosis SW establishment of CLIA Lab precision diagnosis platform as its main business by utilizing precision diagnosis platform and healthcare data analysis technology in the US market.
It plans to commercialize ' data-based cancer early diagnosis technology ' by applying cancer genome data accumulated through cancer data analysis services to AI precision diagnosis software to increase diagnosis accuracy and strengthen predictive power . In addition , CLIA Lab's strategic investment and business cooperation are also promoted . Separately from the acquisition of the local CLIA Lab in the US, the supply of NGENBIO's NGS precision diagnosis products is also planned in earnest through partnerships with CLIA Labs in the US, such as the CLIA Lab, which LabGenomics is planning to acquire recently.
In particular, as the demand for precision diagnosis such as NGS increases in the US market , the need for bioinformatics ( Bioinformatics ) software that can accurately analyze complex biometric data is increasing . “ NGeneAnalySys is being used for precise cancer diagnosis and analysis not only in Korea but also in overseas medical institutions in Europe and the Middle East , ” said an official from NGene Bio.
Choi Dae-chul, CEO of NGNBio, emphasized, “ NGENBIO’s precise diagnosis SW technology is being evaluated as excellent in performance and quality by clinicians to the extent that it is being used in clinical trials for cancer patients at domestic and foreign medical institutions.” He emphasized, “With the establishment of NGENBIO AI, we will increase the accuracy of cancer precision diagnosis by expanding NGENBIO SW to the US medical market, and speed up the ongoing strategic investment in the CLIA Lab to complete within the year. ”
Source: ngenebio.com